Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic ...
Biomarkers are key to the development of biological drugs, offering vital insights into drug mechanisms of action (MOA), informing clinical study design, and optimizing treatment strategies.
--Reduced checkpoint inhibitor activity of GIGA-564 versus current anti-CTLA-4 inhibitors results in superior anti-tumor activity and lower toxicity in murine models ----Data supports advancement of ...
In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven ...
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA ...
Hydralazine, a drug commonly used to treat high blood pressure and preeclampsia, may also help stop the growth of glioblastoma, an aggressive brain tumor, new research suggests.
HONOLULU — Glovadalen (UCB), an investigational brain-penetrant D1 receptor positive allosteric modulator (D1 PAM), is both safe and effective for patients with advanced Parkinson’s disease (PD), new ...
Temferon shows consistent survival metrics in glioblastoma patients with unmethylated MGMT, with 44% reaching 18-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results